阿茲海默失智症藥物治療的現況與新進展

Pharmacological Treatment of Alzheimer's Disease: The Present and the Future

孫瑜(Yu Sun)

阿玆海默失智症 ； 乙醯膽鹼酶抑制劑 ； 治療 ； 臨床試驗 ； 類澱粉蛋白 ； Alzheimer's disease ； cholinesterase inhibitors ； treatment ； clinical trials ； amyloid β peptides

應用心理研究

55期（2012 / 09 / 01）

37 - 58

繁體中文

阿玆海默失智症是失智症中最常見的一種退化性失智症，但目前無有效根治的療法。臨床上常用的藥物主要是針對改善記憶功能及生活功能或減緩其惡化，以及控制其精神症狀的藥物。本研究利用Cochrane資料庫探討自2000年至2012年止，搜尋所有關於阿茲海默失智症臨床試驗的系統性回顧之文章，分析用藥種類及治療效果，本回顧針對目前研究較多的及臨床常用的藥物治療，選取乙醯膽醶酶抑制劑，及N-甲基-D-天冬氨酸（N-methyl-D-aspartic acid, NMDA）接受器拮抗劑，血管預防性用藥，維他命製劑等作文獻回顧，探討其對阿茲海默失智症的療效。另外也針對免疫療法的進展作整理。結果顯示目前最多實證研究及有正面效果的仍是乙醯膽鹼酶抑制劑，有效治療對象是輕到重度之阿茲海默失智症，其療效在於改善記憶功能，生活能力及整體印象分數，有很好的結果。NMDA接受器拮抗劑用於中重度之阿茲海默失智症，在改善記憶功能及生活能力，也有很好的結果。至於神經保護劑、血管改善用藥（如降血脂藥）、及維他命製劑則還沒有足夠多的臨床證據證實其確實有預防及緩解療程惡化的效果，這還須未來更多的研究來證實。近幾年很多臨床試驗用免疫療法，清除或減少「β類澱粉蛋白」來防治失智症，有相當不錯的進展，相信不久的未來，此種治療應該有很大的突破。

Alzheimer's disease (AD) is a progressive, degenerative disorder of the brain and the most common form of dementia among the elderly. With the lack of a cure for AD, goals of drug therapy include temporary improvement, stabilization, or less -than-expected decline in cognition, daily living functions and behavior symptoms. We searched Cochrane database of systematic reviews from year 2000 to 2012 for all the clinical t rails about the pharmacological treatment of AD. The current pharmacological approach of AD treatment is mainly based on symptomatic therapy with cholinesterase inhibitors (ChEIs) and N-methyl-D-aspartic acid (NMDA) receptor antagonists. The results show that treatment with ChEIs in mild to severe dementia of AD patients and NMDA receptor antagonists in moderate to severe AD produced statistically significant improvements in cognition, daily living functions, global clinician's or caregiver's impressions, and behavior symptoms. In recent years, increased emphasis has been put on the vascular contribution to AD's pathophysiology. The two vascular risk factors mostly studied with respect to cognitive outcomes are hypertension and dyslipidemia. In the limited clinical trials using statin to treat AD or dementia, statin caused no significant difference in global function, behaviors, or daily activities, nor is there evidence thus far that statin aids in the prevention of AD or dementia. With regard to vitamin E, an antioxidant, no significant preventive effects were found for the progression from mild cognitive impairment to AD. Other vitamin agents studied for the treatment of dementia are folic acid and vitamin B12. Although these vitamins can lower serum level of homocystien (a reported possible risk factor for AD), no significant beneficial effects were found. Amyloid β (Aβ) peptides represent an important molecular target for AD intervention. Several types of Aβ peptide immunotherapy of AD are currently under investigation. Although pre-clinical studies showed that immunization against Aβ peptide provides protection from and reversal of the pathology of AD in animal models, serious adverse events have been reported like meningoencephalitis and vasogenic edema. Novel strategies have been implemented to overcome these problems. Over 10, 000 patients are enrolled in more than 40 ongoing clinical trials, most of which are expected to report final results in the near future.

1. Alzheimer''s Disease International(2009).,未出版
2. Andersen, C. K.,Lauridsen, J.,Andersen, K.,Kragh-Sorensen, P.(2003).Cost of dementia: Impact of disease progression estimated in longitudinal data.Scandinavian Journal of Public Health,31(2),119-125.
3. Areosa, S. A.,Sherriff, F.(2003).Memantine for dementia.Cochrane Database Systematic Reviews,3
4. Asuni, A. A.,Boutajangout, A.,Quartermain, D.,Sigurdsson, E. M.(2007).Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements.Journal of Neuroscience,27(34),9115-9129.
5. Bayer, A. J.,Bullock, R.,Jones, R. W.,Wilkinson, D.,Paterson, K. R.,Jenkins, L.,Donoghue, S.(2005).Evaluation of the safety and immunogenicity of synthetic Abeta42(AN1792) in patients with AD.Neurology,64(1),94-101.
6. Berr, C.,Richard, M. J.,Roussel, A. M.,Bonithon-Kopp, C.(1998).Systemic oxidative stress and cognitive performance in the population-based EVA study. Etude du Vieillissement Arteriel.Free Radical Biology and Medicine,24(7-8),1202-1208.
7. Birks, J.(2006).Cholinesterase inhibitors for Alzheimer's disease.Cochrane Database of Systematic Reviews,1
8. Birks, J.,Flicker. L.(2006).Donepezil for mild cognitive impairment.Cochrane Database of Systematic Reviews,3
9. Birks, J.,Grimley Evans, J.,Iakovidou, V.,Tsolaki. M.,Holt, F. E.(2009).Rivastigmine for Alzheimer's disease.Cochrane Database of Systematic Reviews,2
10. Birks, J.,Harvey, R. J.(2003).Donepezil for dementia due to Alzheimer's disease.Cochrane Database Systematic Reviews,1
11. Black, S. E.,Doody, R.,Li, H.,McRae, T.,Jambor, K. M.,Xu, Y.,Sun, Y.,Perdomo, C. A.,Richardson, S.(2007).Donepezil preserves cognition and global function in patients with severe Alzheimer disease.Neurology,69(5),459-469.
12. Butterfield, D. A.,Castegna, A.,Drake, J.,Scapagnini, G.,Calabrese, V.(2002).Vitamin E and neurodegenerative disorders associated with oxidative stress.Nutritional Neuroscience,5(4),229-239.
13. Clegg, A.,Bryant, J.,Nicholson, T.,McIntyre, L.,De Broe, S.,Gerard, K.,Waugh, N.(2002).Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review.International Journal of Technology Assessment In Health Care,18(3),497-507.
14. Craig, D.,Birks, J.(2006).Galantamine for vascular cognitive impairment.Cochrane Database of Systematic Reviews,1
15. Cramer, C.,Haan, M. N.,Galea, S.,Langa, K. M.,Kalbfleisch, J. D.(2008).Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study.Neurology,71(5),344-350.
16. Cribbs, D. H.(2010).Abeta DNA vaccination for Alzheimer's disease: Focus on disease prevention.CNS & Neurological Disorders-Drug Targets,9(2),207-216.
17. Cummings, J. L.(2004).Alzheimer's disease.New England Journal of Medicine,351(1),56-67.
18. Deane, R.,Sagare, A.,Hamm, K.,Parisi, M.,LaRue, B.,Guo, H.,Wu, Z.,Holtzman, D. M.,Zlokovic, B. V.(2005).IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor.Journal of Neuroscience,25(50),11495-11503.
19. Delrieu, J.,Ousset, P. J.,Caillaud, C.,Vellas, B.(2012).Clinical trials in Alzheimer's disease': Immunotherapy approaches.Journal of Neuroscience,120(Suppl 1),186-193.
20. Dhillon, S.(2011).Spotlight on rivastigmine transdermal patchdagger: In dementia of the Alzheimer's type.Drugs & Aging,28(11),927-930.
21. Francis, P. T.,Palmer, A. M.,Snape, M.,Wilcock, G. K.(1999).The cholinergic hypothesis of Alzheimer's disease: A review of progress.Journal of Neurology Neurosurgery and Psychiatry,66(2),137-147.
22. Frenkel, D.,Katez, O.,Solomon, B.(2000).Immunization against Alzheimer's beta-amyloid plaques via EFRH phage administration.Proceedings of the National Academy of Sciences of the United States of America,97(21),11455-11459.
23. Fu, H. J.,Liu, B.,Frost, J. L.,Lemere, C. A.(2010).Amyloid-beta immunotherapy for Alzheimer's disease.CNS & Neurological Disorders-Drug Targets,9(2),197-206.
24. Grodstein, F.,Chen, J.,Willett, W. C.(2003).High-dose antioxidant supplements and cognitive function in community-dwelling elderly women.American Journal of Clinical Nutrition,77(4),975-984.
25. Hardy, J.,Adolfsson, R.,Alafuzoff, I.,Bucht, G.,Marcusson, J.,Nyberg, P.,Perdahl, E.,Wester, P.,Winblad, B.(1985).Transmitter deficits in Alzheimer's disease.Neurochemistry International,7(4),545-563.
26. Harris, M. E.,Hensley, K.,Butterfield, D. A.,Leedle, R. A.,Carney, J. M.(1995).Direct evidence of oxidative injury produced by the Alzheimer's beta-amyloid peptide (1-40) in cultured hippocampal neurons.Experimental Neurology,131(2),193-202.
27. Higgins, J. P.,Flicker, L.(2000).Lecithin for dementia and cognitive impairment.Cochrane Database of Systematic Reviews,4
28. Homma, A.,Imai, Y.,Tago, H.,Asada, T.,Shigeta, M.,Iwamoto, T.,Takita, M.,Arimoto, I.,Koma, H.,Ohbayashi, T.(2008).Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: Results from a 24-week, double-blind, placebo-controlled, randomized trial.Dementia and Geriatric Cognitive Disorders,25(5),399-407.
29. Howard, R.,McShane, R.,Lindesay, J.,Ritchie, C.,Baldwin, A.,Barber, R.,Phillips, P.(2012).Donepezil and memantine for moderate-to-severe Alzheimer's disease.New England Journal of Medicine,366(10),893-903.
30. Isaac, M. G.,Quinn, R.,Tabet, N.(2008).Vitamin E for Alzheimer's disease and mild cognitive impairment.Cochrane Database of Systematic Reviews,3
31. Jaturapatporn, D.,Isaac, M. G.,McCleery, J.,Tabet, N.(2012).Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease.Cochrane Database of Systematic Reviews,2
32. Kirby, J.,Green, C.,Loveman, E.,Clegg, A.,Picot, J.,Takeda, A.,Payne, E.(2006).A systematic review of the clinical and cost-effectiveness of memantine in patients with moderately severe to severe Alzheimer's disease.Drugs & Aging,23(3),227-240.
33. Kivipelto, M.,Ngandu, T.,Laatikainen, T.,Winblad, B.,Soininen, H.,Tuomilehto, J.(2006).Risk score for the prediction of dementia risk in 20 years among middle aged people: A longitudinal, population-based study.Lancet Neurology,5(9),735-741.
34. Laake, K.,Oeksengaard, A. R.(2002).D-cycloserine for Alzheimer's disease.Cochrane Database of Systematic Reviews,2
35. Lopez-Arrieta, J. M.,Birks, J.(2002).Nimodipine for primary degenerative, mixed and vascular dementia.Cochrane Database of Systematic Reviews,3
36. Loy, C,Schneider, L.(2006).Galantamine for Alzheimer's disease and mild cognitive impairment.Cochrane Database of Systematic Reviews,1
37. Luchsinger, J. A.,Tang, M. X.,Shea, S.,Mayeux, R.(2003).Antioxidant vitamin intake and risk of Alzheimer disease.Archives of Neurology,60(2),203-208.
38. Malouf, M.,Grimley, E. J.,Areosa, S. A.(2003).Folic acid with or without vitamin B12 for cognition and dementia.Cochrane Database of Systematic Reviews,4
39. Malouf, R.,Areosa, S. A.(2003).Vitamin B12 for cognition.Cochrane Database of Systematic Reviews,3
40. Malouf, R.,Birks, J.(2004).Donepezil for vascular cognitive impairment.Cochrane Database of Systematic Reviews,1
41. Masaki, K. H.,Losonczy, K. G.,Izmirlian, G.,Foley, D. J.,Ross, G. W.,Petrovitch, H.,Havlik, R.,White, L. R.(2000).Association of vitamin E and C supplement use with cognitive function and dementia in elderly men.Neurology,54(6),1265-1272.
42. Mattson, M. P.,Cheng, B.,Davis, D.,Bryant, K.,Lieberburg, I.,Rydel, R. E.(1992).Beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity.Journal of Neuroscience,12(2),376-389.
43. McGuinness, B.,Craig, D.,Bullock, R.,Passmore, P.(2009).Statins for the prevention of dementia.Cochrane Database of Systematic Reviews,2
44. McGuinness, B.,O''Hare, J.,Craig, D.,Bullock, R.,Malouf, R.,Passmore, P.(2010).Statins for the treatment of dementia.Cochrane Database of Systematic Reviews,8
45. McGuinness, B.,Todd, S.,Passmore, P.,Bullock, R.(2009).Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia.Cochrane Database of Systematic Reviews,4
46. Menendez-Gonzalez, M.,Perez-Pinera, P.,Mart inez-Rivera, M.,Muniz, A. L.,Vega, J. A.(2011).Immunotherapy for Alzheimer's disease: Rational basis in ongoing clinical trials.Current Pharmaceutical Design,17(5),508-520.
47. Mohan, M.,Bennett, C.,Carpenter, P. K.(2009).Galantamine for dementia in people with Down syndrome.Cochrane Database of Systematic Reviews,1
48. Mohan, M.,Bennett, C.,Carpenter, P. K.(2009).Rivastigmine for dementia in people with Down syndrome.Cochrane Database of Systematic Reviews,1
49. Morris, M. C.,Evans, D. A.,Bienias, J. L.,Tangney, C. C.,Wilson, R. S.(2002).Vitamin E and cognitive decline in older persons.Archives of Neurology,59(7),1125-1132.
50. Nagano, S.,Huang, X.,Moir, R. D.,Payton, S. M.,Tanzi, R. E.,Bush, A. I.(2004).Peroxidase activity of cyclooxygenase-2 (COX-2) cross-links beta-amyloid (Abeta) and generates Abeta-COX-2 hetero-oligomers that are increased in Alzheimer's disease.Journal of Biological Chemistry,279(15),14673-14678.
51. Okura, Y.,Kohyama, K.,Park, I. K.,Matsumoto, Y.(2008).Nonviral DNA vaccination augments microglial phagocytosis of beta-amyloid deposits as a major clearance pathway in an Alzheimer disease mouse model.Journal of Neuropathology And Experimental Neurology,67(11),1063-1071.
52. Pitchumoni, S. S.,Doraiswamy, P. M.(1998).Current status of antio xidant therapy for Alzheimer's Disease.Journal of the American Geriatrics Society,46(12),1566-1572.
53. Preey, E. K.(1986).The Cholinergic hypothesis-ten years on.British Medical Bulletin,42(1),63-69.
54. Querfurth, H. W.,LAFerla, F. M.(2010).Alzheimer's disease.New England Journal of Medicine,362(4),329-344.
55. Reisberg, B.,Doody, R.,Stoffler, A.,Schmitt, F.,Ferris, S.,Mobius, H. J.(2003).Memantine in moderate-to-severe Alzheimer's disease.New England Journal of Medicine,348(14),1333-1341.
56. Riordan, K. C.,Hoffman Snyder, C. R.,Wellik, K. E.,Caselli, R. J.,Wingerchuk, D. M.,Demaerschalk, B. M.(2011).Effectiveness of adding memantine to an Alzheimer dementia treatment regimen which already includes stable donepezil therapy: A critically appraised topic.Neurologist,17(2),121-123.
57. Rodriguez-Martin, J. L.,Qizilbash, N.,Lopez-Arrieta, J. M.(2001).Thiamine for Alzheimer's disease.Cochrane Database of Systematic Reviews,2
58. Rolinski, M.,Fox, C.,Maidment, I.,McShane, R.(2012).Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.Cochrane Database of Systematic Reviews,3
59. Selkoe, D. J.(2004).Alzheimer's disease: Mechanistic understanding predicts novel therapies.Annals Internal Medicine,140(8),627-638.
60. Seshadri, S.,Beiser, A.,Selhub, J.,Jacques, P. F.,Rosenberg, I. H.,D''Agostino, R. B.,Wilson, P. W.,Wolf, P. A.(2002).Plasma homocysteine as a risk factor for dementia and Alzheimer's disease.New England Journal of Medicine,346(7),476-483.
61. Sun, Y.,Lai, M. S.,Lu, C. J.,Chen, R. C.(2008).How long can patients with mild or moderate Alzheimer's dementia maintain both the cognition and the therapy of cholinesterase inhibitors: A national population-based study.European Journal of Neurology,15(3),278-283.
62. Sun, Y.,Lu, C. J.,Chien, K. L.,Chen, S. T.,Chen, R. C.(2007).Efficacy of multivitamin supplementation containing vitamins B6 and B12 and folic acid as adjunctive treatment with a cholinesterase inhibitor in Alzheimer's disease: A 26-week, randomized, double-blind, placebo-controlled study in Taiwanese patients.Clinical Therapeutics,29(10),2204-2214.
63. Tabet, N.,Feldmand, H.(2003).Ibuprofen for Alzheimer's disease.Cochrane Database of Systematic Reviews,2
64. Winblad, B.,Kilander, L.,Eriksson, S.,Minthon, L.,Batsman, S.,Wetterholm, A. L.,Jansson-Blixt, C.,Haglund, A.(2006).Donepezil in patients with severe Alzheimer's disease: Double-blind, parallel-group, placebo-controlled study.Lancet,367(9516),1057-1065.
65. Yamada, K.,Yabuki, C.,Seubert, P.,Schenk, D.,Hori, Y.,Ohtsuki, S.,Terasaki, T.,Hashimoto, T.,Iwatsubo, T.(2009).Abeta immunotherapy: Intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta.Journal of Neuroscience,29(36),11393-11398.
66. Zandi, P. P.,Anthony, J. C.,Khachaturian, A. S.,Stone, S. V.,Gustafson, D.,Tschanz, J. T.,Norton, M. C.,Welsh-Bohmer, K. A.,Breitner, J. C(2004).Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: The Cache County Study.Archives of Neurology,61(1),82-88.
67. 呂建榮,孫瑜(2012).Statins use and risk of incident dementia-A nationwide population-based study.27th International Conference of Alzheimer's disease,London, England:
68. 孫瑜,邱銘章,李明濱(2009).阿茲海默失智症的食療科學證據.臺灣醫界,52(11),8-12.

1. 徐冠馨(2017)。麻醉與阿茲海默症風險之相關性。長榮大學醫務管理學系(所)學位論文。2017。1-77。